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a  b  s  t  r  a  c  t
Proximity  assays  are  immunohistochemical  tools  that  utilise  two  or more  DNA-tagged  aptamers  or  anti-
bodies  binding  in  close  proximity  to  the same  protein  or protein  complex.  Ampliﬁcation  by PCR or
isothermal  methods  and  hybridisation  of  a  labelled  probe  to its DNA  target  generates  a signal  that  enables
sensitive  and  robust  detection  of  proteins,  protein  modiﬁcations  or  protein–protein  interactions.  Assayseywords:
mmunoassays
mmuno-PCR
roximity ligation assay
can be  carried  out in homogeneous  or solid  phase  formats  and  in  situ  assays  can  visualise  single  protein
molecules  or  complexes  with high  spatial  accuracy.  These  properties  highlight  the  potential  of  proxim-
ity  assays  in  research,  diagnostic,  pharmacological  and  many  other  applications  that  require  sensitive,
speciﬁc  and  accurate  assessments  of protein  expression.
©  2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CCroximity extension assay
n situ assays BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
The remarkable advances made over the last ﬁfty years or so in
ll areas of the life sciences, medicine, diagnostics, forensics and
iotechnology are inconceivable without the contributions from
wo key technologies: the polymerase chain reaction (PCR) for
he detection of nucleic acids and antibody-based methods for the
etection of proteins.
of gene expression, as well as a pervasive presence in diagnos-
tic assays aimed at identifying pathogens [1]. The introduction of
real-time quantitative PCR (qPCR) [2–4], which uses ﬂuorescence
to detect PCR amplicons provided a simple and reproducible
method for the detection of nucleic acids and, crucially, affords
the very large dynamic range required for accurate quantiﬁcation
of mRNA.
• Antibodies are characterised by their diversity, speciﬁcity and
ability to bind to target epitopes in complex biological samplesPCR is typiﬁed by its exquisite sensitivity and simplicity of use, for
example the ease with which speciﬁc primers can be synthesised
and modiﬁed. These properties have led to the widespread use of
PCR and its complement, reverse transcription (RT)-PCR, for the
analysis of mutations, SNPs and DNA methylation, the analysis
∗ Corresponding author. Tel.: +44 08451963570.
E-mail address: Stephen.bustin@anglia.ac.uk (S.A. Bustin).
ttp://dx.doi.org/10.1016/j.bdq.2015.04.002
214-7535/© 2015 The Authors. Published by Elsevier GmbH. This is an open access artic
.0/[by-nc-nd/4.0/]).such as serum and whole cell lysates. They are used in a wide
range of immunoassays, e.g. the enzyme-linked immunosorbent
assay (ELISA) [5], which measure signals emanating from the
afﬁnity interactions of antibodies with their target molecules.
Antibodies are also an essential component of ﬂow cytometry,
which allows the analysis of the expression of cell surface and
intracellular molecules, characterisation and deﬁnition of differ-
ent cell types in heterogeneous cell populations, assessment of
the purity of isolated subpopulations, and analysis of cell size and
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. The original iPCR made use of a recombinant streptavidin-protein A chimera
with bispeciﬁc afﬁnity for DNA and antibodies to link linear plasmid DNA to an
antibody speciﬁc for bovine serum albumin (BSA), which was immobilised on theC. Greenwood et al. / Biomolecular De
volume. This has enabled the detailed study of cellular protein
expression, location, modiﬁcation and interaction [6], the dis-
covery of protein biomarkers in serum and plasma for diagnostic
applications such as early detection and monitoring of disease
[7] and the rapid and speciﬁc detection of pathogen-speciﬁc
proteins [8] together with the emergence of antibody-derived
drug-conjugate molecules as promising next generation thera-
peutics [9].
The ever-increasing availability of new antibodies continues to
xpand the potential of the immunohistochemical repertoire. At
he same time, there has been a continuous stream of improve-
ents and novel developments of nucleic-acid detection methods,
ncluding the emergence of isothermal ampliﬁcation methods such
s rolling circle ampliﬁcation (RCA) [10]. The combination of these
echnologies, leading ﬁrst to the development of immuno-PCR
iPCR) and, more recently proximity ligation (PLA) and extension
PEA) assays, couples the detection speciﬁcity of the antibody with
he ampliﬁcation power of PCR or RCA. This arsenal is beginning
o provide researchers with a powerful tool for the detection and
uantiﬁcation of cellular, pathogen and GMO-speciﬁc proteins as
ell as diagnostic biomarkers [11]. This emergence of proximity
ssays into the main stream of proteomic research is reﬂected in
he number of papers citing the technology, which have increased
ourfold between 2010 and 2014 from 41 to 156, with 55 papers
lready published in 2015.
. Immuno-PCR
The original iPCR, which was ﬁrst described in 1992 [12],
nvolved ampliﬁcation of a biotinylated, linear plasmid DNA
inked to antigen/monoclonal antibody complexes immobilised on
icrotiterplate wells through a streptavidin-protein A chimera
Fig. 1). This modiﬁcation signiﬁcantly enhanced the sensitivity of
n equivalent ELISA, permitting the detection of as few as several
undred targets by means of ethidium bromide-stained agarose
el electrophoresis. Additional changes created a more universal
PCR by substituting the fusion protein with commercially available
iotinylated secondary antibodies, thus circumventing the vari-
bility and lack of speciﬁcity associated with the use of protein
 [13]. Although assay throughput and sensitivity was increased
urther when readout by gel electrophoresis was replaced with
uorogenic PCR-ELISA [14], iPCR still required time-intensive and
aborious post-PCR analysis. This was addressed by using qPCR
o detect antigen/antibody complexes, which simpliﬁed iPCR by
educing the number of handling steps and, crucially, increased the
ynamic range of the assay [15,16]. Eventually, the most advan-
ageous assay format was identiﬁed as consisting of a sandwich
ssemblage: a capture antibody is adsorbed directly to the surface
f a PCR plate well, sample and detection antibody, which is cou-
led to a DNA-label, are premixed and transferred to the PCR plate
17]. At the time, the marker DNA was covalently coupled to the
ntibody, but since the covalent conjugation of oligonucleotides
o antibodies can be difﬁcult and time consuming, this has now
een largely replaced by a combination of biotinylated antibodies
nd streptavidin-linked oligonucleotides. Today, iPCR in its vari-
us manifestations has become a robust method that provides the
peciﬁcity and sensitivity required e.g. for assessing the success of
ovel drug design [18] or measuring the pharmacokinetics [19] and
oxicokinetics [20] of drug metabolism. It has also been used for the
etection of protein biomarkers of cancers [21–25] and viral infec-
ious agents [26,27]. Chimera Biotec (http://www.chimera-biotec.
om) is the best-known provider of iPCR-based assays and assay
evelopment services with numerous applications targeting many
inds of macromolecular analyte.surface of microtitre wells. Binding of the antibody to BSA resulted in a speciﬁc
antigen–antibody–DNA conjugate that was  detected by agarose gel electrophoresis
after PCR ampliﬁcation with plasmid-speciﬁc primers.
3. Proximity ligation assays
Arguably the main drawbacks of iPCR are its non-homogeneous
nature, which requires extensive washing steps to ensure minimal
background signal. Proximity assays address this issue and the ﬁrst
of these, PLA, was ﬁrst demonstrated in 2002 [28]. At ﬁrst, PLA made
use of two DNA aptamers [29], which bind their targets with afﬁni-
ties and speciﬁcities that are comparable to those of monoclonal
antibodies [30] and can be designed so that they only require a
single epitope on a protein surface [31]. However, difﬁculties with
aptamer design and the availability of a vast pool of commercial
antibodies has resulted in antibody-based PLAs becoming the most
popular way of implementing this assay [32]. Today, the most com-
mon  method uses two antibodies, with the requirement for a dual
binding event making a false positive result less likely and thus
reducing background noise.
PLA probes are assembled either through noncovalent attach-
ment of biotinylated oligonucleotides to streptavidin and subse-
quent interaction of that complex with biotinylated antibodies [33]
or, more commonly today, through generation of oligonucleotides
covalently attached to streptavidin at either their 5′- or 3′-ends,
allowing them to interact directly with biotinylated antibodies. PLA
can use either monoclonal or polyclonal antibodies, as well as a
combination of the two. There are two  alternative approaches for
detecting the antibody/antigen interaction: one uses direct primary
antibody conjugation (Fig. 2A), the other indirect scheme uses a
secondary antibody linked to DNA for detection (Fig. 2B). It is also
possible to conjugate oligonucleotides directly to Fab fragments,
which improves the dimensional detection limit of PLA [34]. At its
simplest, a single biotinylated monoclonal antibody can be divided
into two  groups for conjugation with a 5′- or 3′-oligonucleotide,
12 C. Greenwood et al. / Biomolecular Detection and Quantiﬁcation 4 (2015) 10–16
Fig. 2. Direct and indirect PLA. (A) Biotinylated antibodies bind pairwise to adjacent epitopes on target proteins. This brings the two streptavidin-oligonucleotide tails, one
coupled through its 5′-end, the other through its 3′-end, into close proximity. The connector oligonucleotide (splint) hybridises to both oligonucleotides, resulting in adjacent
free  3′-OH and 5′-phosphate moieties. The gap is ligated and the resulting continuous DNA strand can be ampliﬁed and detected. (B) The indirect form of PLA follows the
same  principle, except that unmodiﬁed primary antibodies are detected with secondary antibodies that are conjugated to the DNA strands.
Fig. 3. PLA workﬂow. (A) Oligonucleotides synthesised with a streptavidin molecule at their 5′- or 3′-ends are combined with biotinylated antibodies to form proximity
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Trobes.  (B) Probes, sample and splint are combined and both probes bind simultaneo
re  joined by the splint. (C) DNA ligase connects the gap and thus joins the two  ol
etected by several methods. (E) Detection by qPCR or dPCR is shown.
espectively (Fig. 3A). This design is applicable to antigen targets
ssembled in multimeric formats such as protein homodimers and
epeated motifs expressed on the surfaces of virions. The subse-
uent workﬂow is both simple and rapid and following a 60 min
nnealing of antibodies, antigen and splint in a microtitre plate
Fig. 3B), a brief 10 min  ligation (Fig. 3C) generates ampliﬁable DNA
emplates (Fig. 3D) that can be detected using a number of differ-
nt readout formats. Fig. 3E shows results obtained using a standard
PCR thermal cycler (CFX Connect, Biorad, Hercules, CA, USA) or a
igital PCR (Constellation, Formulatrix, Bedford, MA,  USA) setup. In
ddition, ﬂow cytometry [35], loop-mediated isothermal ampliﬁ-
ation [36] or DNA sequencing [37,38] have also been employed.
he indirect form of PLA follows the same principle, except thato their epitopes on the target antigen, if present, and the 5 - and 3 -oligonucleotides
leotides. (D) This generates a full length DNA amplicon that can be ampliﬁed and
unmodiﬁed primary antibodies are detected with secondary anti-
bodies that are conjugated to the DNA strands.
The intra-assay coefﬁcients of variation (CVs) with qPCR as read-
out range from less than 10% to greater than 30% [39]. This has
been improved by the development of a digital PLA (dPLA) based
on ampliﬁed single molecule detection, which shows signiﬁcant
improvements in precision and detection sensitivity over qPCR
readout [40]. The dPLA workﬂow is the same as that for standard
PLA up to and including the ligation step. Instead of PCR ampliﬁ-
cation, two  oligonucleotides complementary to either end of the
single stranded oligonucleotides connecting the two antibodies
are added, generating two  restriction sites. Following digestion,
released DNA strands are circularised via a second DNA ligation
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eaction and the circularised reporter DNA molecules are ampli-
ed, in this case by RCA. Ampliﬁcation products form random coils,
hich after are detected by hybridisation with ﬂuorescence dye
abelled probes and counted using a dedicated microﬂuidic detec-
ion instrument.
PLAs can be carried out in solution as a homogeneous assay,
hich has the advantage of minimising operator intervention, obvi-
ting the requirement for washes and hence facilitating maximum
peed. Like immuno-PCR, PLA can also be conﬁgured in a solid phase
ormat using an immobilised capture antibody, with two  proximity
robes detecting captured target molecules [41], an approach that
ay  be more suitable for detecting protein directly from bioﬂuids
uch as blood or faeces (Fig. 4A). Conﬁguring the assay through the
inding of three independent afﬁnity reagents to the same target
olecule can further enhance speciﬁcity of signal generation [42].
n this triple antibody speciﬁc proximity ligation assay, the third
roximity ligation probe replaces the connector oligonucleotide
s a ligation template. Short blocking oligonucleotides prevent
igation in the absence of the target molecule and considerably
inimise background noise.
Another proximity-mediated detection system, in situ PLA,
an detect and visualise target proteins and protein complexes
xpressed by ﬁxed cells and on tissue slide sections [43,44]. In situ
LA uses RCA to amplify ligation products, which are generated
hrough the ligation of two connector oligonucleotides to the two
ligonucleotides conjugated to the antibodies. This results in the
ormation of a circular, single stranded DNA molecule, with one of
he antibody-conjugated DNA molecules serving as a primer for the
CA. Following the addition of a DNA polymerase, a long DNA prod-
ct is formed that remains covalently attached to one of the PLA
robes. Consequently, a concatameric repeat of the same sequence
ggregates in submicron spots, generating discrete, localised sig-
als after hybridisation of ﬂuorescence-labelled oligonucleotide
robes complementary to the RCA product. Signals can be detected
nd digitally counted using a standard ﬂuorescence microscope
45–49]. The reaction is so efﬁcient that care must be taken when
sing RCA in a quantitative manner due to the possibility of non-
inear saturation of the RCA signal [50].
Multiplex PLAs have been developed, where the ligation of
umerous PLA probes linked to different combinations of 5′- and 3′-
ligonucleotides results in unique sequences that serve as primer
ites for target-speciﬁc ampliﬁcation and quantiﬁcation by qPCR
51]. This has been extended so that four 24-plex panels proﬁling
4 putative biomarkers can be analysed with high sensitivity, yet
sing very low levels of sample [52]. Kits for carrying out homo-
eneous PLAs are commercially available from Life Technologies,
arlsbad, CA, USA, those for in situ PLA from Olink Bioscience, Upp-
ala, Sweden or Sigma–Aldrich, St. Louis, Mo,  USA.
. Proximity extension assays
PEA is an alternative to PLA and was developed because prox-
mity probes joined by a DNA ligase suffer from recovery loss in
omplex biological ﬂuids [53]. The main difference between the two
s that in a PEA the ligation event is replaced by a DNA polymerisa-
ion step. In its original design, one of the PEA probes consisted of
 double stranded-oligonucleotide attached to the antibody at its
′-end, with a nine nucleotide or so 3′-overhang at its 5′-end. This
verhang was complementary to the 3′-end of the oligonucleotide
ound to the other antibody partner (Fig. 4B). Following incubation
f the proximity probes with a sample containing antigen recog-
ised by the probes, the overhanging 3′-end could hybridise to
he 5′-oligonucleotide and, following the addition of a DNA poly-
erase, the free 3′-OH was extended in the 5′–3′ direction towards
he attachment site of the 5′-oligonucleotide. This generated an and Quantiﬁcation 4 (2015) 10–16 13
full-length amplicon and hybridisation site for the upstream primer
and thus allows for the ampliﬁcation and detection of the target
antigen by PCR. This arrangement has now been replaced by a mod-
iﬁcation, where each of the two single-stranded oligonucleotides
contain a complementary site for pair-wise annealing with the
other oligonucleotide, allowing extension by a DNA polymerase
[54]. This obviates the requirement for a double-stranded oligonu-
cleotide with a 3′-overhang (Fig. 4C). Furthermore, judicious choice
of DNA polymerase allows minimisation of background noise and
so improves the sensitivity of the assay [54]. PEA is amenable to
multiplexing [54,55] and features the same advantages of PLA,
including very low sample consumption, high sensitivity and speci-
ﬁcity detection in a homogeneous reaction [7]. For maximum
sensitivity, PEA requires the use of DNA polymerases with intact
3′–5′ exonuclease as they reduce background noise by degrading
non-proximal DNA strands. Kits for carrying out PEAs are commer-
cially available from Olink Bioscience, Uppsala, Sweden.
5. Applications
The ultra-low sample requirement of homogeneous PLA and the
ability of solid phase PLA to investigate larger sample volumes has
made this technology a useful tool for a wide range of proteomic
studies [56]. PCR-based assays only detect nucleic acids and cannot
reliably provide information about the relationship between RNA
and cellular protein levels, the extent of post-translational mod-
iﬁcations or protein/protein interactions. This is important, since
transcriptome and proteome are in a constant state of dynamic ﬂux
involving the transcription or degradation of RNAs and the transla-
tion, modiﬁcation, interaction and turnover of proteins. This results
in a complex, variable and sample-dependent [57] relationship
between mRNA levels and protein expression, making extrapola-
tion of changes in RNA levels to those of proteins difﬁcult. Indeed,
somewhere between 30 and 70% of the variability in protein levels
can be explained by concordance to mRNA levels [58,59] and trans-
lation efﬁciency turns out to be the best predictor of protein levels
[60]. This challenge is not conﬁned to nuclear genes, as mitochon-
drial proteins can also show signiﬁcant upregulation in the absence
of any change in mRNA levels [61]. Furthermore, correlations are
very much gene-dependent and are substantially stronger for genes
involved in the maintenance of cellular processes and structural
properties compared with regulatory genes [60].
PLA encourages an integrated approach for measuring relative
changes in miRNA, mRNA and protein expression from the same
starting sample and on a single analytical platform [62]. This makes
it a useful method for the validation of potential biomarkers for
clinical diagnostic needs, for example by simplifying the analy-
sis of cellular protein/protein interactions [63,64], screening for
inhibitors of such interactions and posttranslational modiﬁcations
[65,66] or the interaction of cellular and viral proteins [67]. PLA
is ﬁnding increased use for cancer biomarker proﬁling, where its
multiplexing capabilities [51,68] allow the simultaneous analysis
of tens of proteins at a time [69] and make possible the parallel
visualisation of multiple protein complexes in tumour cells [70,71].
It provides an ultrasensitive assay for the detection of PSA [72]
and has been used for the in situ quantiﬁcation of EGFR receptor
dimerisation and activation [63]. PLA has identiﬁed functional dif-
ferences between different mutations, which may help with the
development of mutation-speciﬁc targeted therapies [73]. Speciﬁ-
cally, its ability to identify mutant EGFR dimer conﬁgurations that
can evade blockade by anti-EGFR treatment may permit a more
accurate patient selection for EGFR-targeted treatment in glioblas-
toma multiforme, the most common primary brain tumour [74]. In
breast cancer, it has been used to demonstrate that elevated lev-
els of HER2:HER2 and HER2:HER3 [75] as well as protein kinase
14 C. Greenwood et al. / Biomolecular Detection and Quantiﬁcation 4 (2015) 10–16
Fig. 4. A. Solid phase PLA. (A) Capture antibody immobilised in a microtitre well binds target antigen, with unbound particles and other sample components removed by
washes. Proximity probes are then added to the well and a PLA is carried out. (B) First generation PEA. The 3′-oligonucleotide is double stranded with a 3′-overhang. In the
presence of target antigen, the probe oligonucleotides can hybridise to each other, leading to the extension of one oligonucleotide into a DNA template that can be detected
and  quantiﬁed. (C) Second generation PEA. Single stranded oligonucleotides hybridise directly to each other, with one becoming extended by a DNA polymerase to generate
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Pn  ampliﬁable DNA template.
:HER2 complexes [66] are signiﬁcantly associated with differ-
nces in overall patient survival. Furthermore, speciﬁc interactions
etween Smad proteins and AP-1 transcription factors activate a
rogramme of TGF-induced breast cancer cell invasion [76], with
kt activation identiﬁed as an important driver of progression [77].
nterestingly, measuring activated forms of Akt by in situ PLA does
ot correlate with phosphorylated Akt or the Akt isoforms as mea-
ured by IHC, suggesting that the isoform-speciﬁc PLA assays are
roviding additional clinically relevant information. PLA is showing
imilar promise for the molecular dissection of a number of other
ancers, including lung [78,79], colorectal [80] and prostate [81]
ancers. There are fewer publications describing the use of PEA, but
his assay has been used to identify ﬁve plasma protein biomarkers
ssociated with colorectal cancer, with three of them additionally
ound to be discriminators of early-stage cancer [55].
Pathogen detection is another application for proximity assays,
uggested by the original proof of concept [41]. PLA has been used
or bacterial [82,83] and viral [84,85] pathogen detection, identiﬁ-
ation of bacterial spores [86] as well as analyses of mechanisms
nderlying viral pathogenicity [87] and may  have a role in the
apid identiﬁcation of pathogens in environmental samples for
iosecurity applications [88]. Proximity assays may  be of partic-
lar interest for the development of assays targeting infectious
ungal diseases, bloodstream and nosocomial infections, which are
ssociated with high rates of morbidity and mortality. Early treat-
ent is the foundation for successful disease management, yet its
iagnosis is challenging due to the limitations of the methods cur-
ently used. Since pathogens are most effectively eliminated in the
arliest stages of infection, there is an urgent need for early detec-
ion of infectious microbes. Current immunodiagnostic methods,
.g. ELISAs and lateral ﬂow devices (LFD) lack the sensitivity for
arliest possible diagnosis. PCR is more sensitive, but the detec-
ion of microbial DNA does not deﬁnitively prove the presence of a
iable microorganism causing a given infection. Furthermore, there
re contamination issues with PCR-based assays, not least because
CR reagents are produced in bacteria and fungi and may  containmicrobial DNA impurities. Proximity assays targeting proteins
expressed only during active growth would provide functional
information and allow earlier, clinically more relevant detection
than ELISA or LFD but without the disadvantages associated with
PCR-based detection [89].
6. Conclusions
Proximity assays expand the range of DNA ampliﬁcation appli-
cations to include the sensitive, accurate and robust identiﬁcation
of proteins through the ampliﬁcation of a surrogate DNA tem-
plate after antibody binding [62]. This provides a variety of novel
approaches for the direct detection of proteins, with the homoge-
nous format of PLA allowing speciﬁc detection and quantiﬁcation
from unfractionated cell lysates and bioﬂuids while in situ PLA
provides a powerful means of localising proteins and interro-
gating protein/protein interactions. Today, most proximity assays
make use of the extensive collection of commercially available
antibodies, although advances in the selection and production of
aptamers are likely to see their use increase in future [90,91]. This
is going to increase the attractiveness of proximity assays for use
as tools for next generation pathology surveillance [92], live cell
imaging [93], unravelling the details of cellular migration char-
acteristic of embryogenesis and cancer metastasis [94] as well as
protein biomarker validation [95] essential for the implementation
of personalised medicine [96]. Furthermore, there is an obvious
application of proximity assays for the detection of pathogens
where the detection of nucleic acids by itself does not indicate
viability or ability to invade [89]. Finally, at this early stage it is
also important to consider benchmarks for assay standardisation,
reproducibility and transparency of reporting [11] analogous to
the MIQE guidelines [97]. In conclusion, proximity assays provide
an integrated approach to the measurement of changes in gene
and protein expression, protein modiﬁcation and interactions from
the same starting sample and readouts on a single analytical
platform.
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